Drug Profile
TPST 1495
Alternative Names: TPST-1495Latest Information Update: 22 Apr 2024
Price :
$50
*
At a glance
- Originator Tempest Therapeutics
- Class Antineoplastics; Small molecules
- Mechanism of Action Prostaglandin E EP2 receptor antagonists; Prostaglandin E EP4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 19 Mar 2024 Tempest Therapeutics in collaboration with NCI plans a phase-II trial for Familial adenomatous polyposis (Monotherapy) in 2H 2024
- 21 Jul 2023 TPST 1495 is still in phase I trial for Solid-tumours(Inoperable/Unresectable, Late-stage disease, Metastatic disease, Monotherapy, Combination therapy) in USA (PO) (NCT04344795)
- 28 Jun 2023 No recent reports of development identified for phase-I development in Solid-tumours(Combination therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease) in USA (PO)